NEW YORK, July 14 (Reuters) - Moderna Inc MRNA.O said on Tuesday that it plans to start late stage clinical trial for its COVID-19 vaccine candidate on or around July 27, according to its listing for the phase 3 study at clinicaltrials.gov.
Moderna said it will conduct the trial at 87 study locations, all in the U.S.
(Reporting by Michael Erman, Editing by Franklin Paul)
((michael.erman@thomsonreuters.com; +1 646-223-6021; Reuters Messaging: michael.erman.thomsonreuters.com@thomsonreuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.